Bayer will develop kidney diseases treatment along with Vanderbilt University

| By | Bayer, Drug Development

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Patients suffering from end-stage renal disease (ESRD) face dialysis, transplantation or palliative care as their only therapeutic options. There is no effective treatment available that can prevent the cardiovascular consequences of chronic kidney disease and at the same time reduce the progression to ESRD. The goal is to develop two new investigational drugs addressing the medical need of ESRD within the time frame of this strategic research alliance.

“We are excited about this partnership with Bayer to develop new drugs and novel therapies to target patients who have kidney diseases and to stop their progression,” said Raymond Harris, M.D., director of Vanderbilt’s Division of Nephrology.

VUMC and Bayer established the agreement to jointly conduct research activities including target validation, assay development and lead optimization. Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer will have an option for the exclusive use of the collaboration’s results.

“Bayer is committed to further expanding its research efforts in the area of renal diseases,” said Andreas Busch, a member of the executive committee of Bayer AG’s Pharmaceuticals Division and head of drug discovery. “We are seeking to join forces with industrial and academic partners to develop innovative drug candidates and to eventually offer patients new treatment options.” Busch said. “Therefore, we are pleased to partner with Vanderbilt University Medical Center, which is among the academic leaders in kidney disease and clinical translation.”

Through the five-year drug discovery project, Vanderbilt will work on various projects to develop a number of potential compounds to be tested and eventually used on patients.